VIR News and Press, Vir Biotechnology Inc. From 02/21/23

Vir Biotechnology ( NASDAQ: VIR ) gained ~9% on Tuesday after Goldman Sachs upgraded the COVID-19 treatment maker to Buy from Hold, citing a post-pandemic leg to its story given its experimental flu vaccine. The upgrade comes as Vir ( VIR ) prepares to report initial data for ...

SAN FRANCISCO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2022, on Thursday, February 23, 2023. The corporate update ...

Summary Pharmaceuticals and biotechnology still look attractive. Healthcare providers are close to their baseline in both valuation and quality. I look at iShares Genomics Immunology and Healthcare ETF, an ETF in genomics and immunology. 10 stocks cheaper than their peers in Nov...

Vir Biotechnology ( NASDAQ: VIR ) appointed Sung Lee as EVP & CFO, effective Mar.27, 2023, post the resignation of Howard Horn, who will leave the company after a brief transition period. Mr. Lee is an experienced CFO with 20+ years of finance leadersh...

– Experienced biotech executive brings more than 20 years of financial leadership to Vir – – Howard Horn departing to pursue next chapter; will remain in an advisory role through a brief transition period – SAN FRANCISCO, Feb. 16, 2023 (GLOBE NEWSWI...

– Vir to continue advancing next-generation COVID-19 solutions independently or with other partners – – The Companies will continue working together to ensure ongoing access to sotrovimab for patients around the world, where authorized, and to advance new t...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips You don’t have to be particularly astute to recognize the importance of the most undervalued biotech stocks to buy. Fundamentally, the enterprises that undergird these names operate on the cutting edge of medical scien...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Healthcare stocks  performed well in 2022, driven by a number of factors. One of the main drivers was the ongoing COVID-19 pandemic, which continued to boost demand for healthcare products and services. That substantia...

Morgan Stanley upgraded COVID-19 drug developer Vir Biotechnology ( NASDAQ: VIR ) to Equal Weight from Underweight on Friday, citing multiple Phase 2 readouts this year across its pipeline for microbial diseases. The analyst Michael Ulz points out that the firm’s previous beari...

Vir Biotechnology ( NASDAQ: VIR ) announced on Wednesday the planned retirement of CEO George Scangos, effective April 3, 2023. Industry veteran Marianne De Backer has been named as Scangos' successor, effective April 3, 2023. De Backer, who currently serves as EVP, Head of Pharma...